Japanese Encephalitis Virus Vaccine Nakayama Dosage

Usual Adult Dose for Japanese Encephalitis Virus Prophylaxis

1 mL subcutaneously on days 0, 7, and 30.
If there are time constraints, three doses may be given on days 0, 7, and 14.
If neither schedule can be followed, two doses given on days 0 and 7 will induce antibodies in up to 80% of recipients; however, this regimen is not recommended.
A booster dose of 1 mL may be given after 2 years. There are no data on optimal spacing of boosters after 2 years.

Available supplies are limited; use is restricted for children 1 to 16 years of age.

No information is available concerning the interchangeability of vaccines; however, because the supply of Japanese encephalitis virus vaccine Nakayama (Je-Vax) is limited, adults 17 years of age or older who require a booster dose may receive a 2 dose primary series of Japanese encephalitis virus vaccine SA14-14-2 (Ixiaro) when Je-Vax is not available and further vaccination is required.

Usual Pediatric Dose for Japanese Encephalitis Virus Prophylaxis

1 year to 2 years: 0.5 mL subcutaneously on days 0, 7, and 30. A booster dose of 0.5 mL may be given after 2 years.
3 years or older: 1 mL subcutaneously on days 0, 7, and 30.

An abbreviated schedule with the third dose administered on day 14 should be used only when time does not permit waiting; 2 doses a week apart produce immunity in about 80% of recipients; the longest regimen yields highest titers after 6 months.

A booster dose of 1 mL may be given after 2 years. There are no data on optimal spacing of boosters after 2 years.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

No adjustment recommended

Precautions

Japanese encephalitis (JE) vaccine is contraindicated in patients who have had angioedema or urticaria after a previous dose of this vaccine, or who are allergic to mouse protein, neural protein, or thimerosal.

Adverse reactions manifesting as generalized urticaria or angioedema may occur within minutes following vaccination. A possibly related reaction has occurred as late as 17 days after vaccination. Most reactions occur within 10 days with the majority occurring within 48 hours.

Patients should be observed for 30 minutes following the administration of JE vaccine and warned about the possibility of delayed generalized urticaria.

Patients should remain in an area where they have immediate access to medical care for 30 days after vaccination and they should seek immediate medical attention if an adverse event develops. They should not embark upon international travel within 10 days of vaccination, due to the possibility of delayed adverse reactions.

Patients should be advised to avoid more than their usual alcohol intake for 48 hours after vaccination because there may be an increased risk of hypersensitivity after unusual amounts of alcohol consumption.

The safety and effectiveness of JE vaccine in pediatric patients less than 1 year have not been established.

Dialysis

Data not available

Other Comments

The lyophilized vaccine should be refrigerated to maintain full potency. Reconstituted vaccine should be refrigerated and used within 8 hours. Do not freeze either the lyophilized or reconstituted vaccine.

Patients should be advised to take additional measures to protect themselves against mosquito bites, such as protective clothing, use of insect repellents, and avoiding outdoor activity during twilight and in the evening.

Adverse reactions should be reported to the U.S. Department of Health and Human Services Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 and the manufacturer.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer